STERIS plc (STE)

In the past six months, STERIS Plc's stock (STE) has experienced a 15.50% increase. Key events impacting the stock price include strong fiscal year 2024 results, the divestiture of the Dental segment, a targeted restructuring plan, stabilization of bioprocessing demand and supply chain improvements, and consistent dividend payments.

Demand for STERIS Plc's products and services is generally stable rather than highly seasonal, due to its focus on non-elective products and services. Increased demand for medical procedures also drives the need for STERIS's offerings. The company's diversified business model helps it navigate market uncertainties and maintain its growth trajectory.

STERIS Plc is a global leader in infection prevention and other procedural products and services, primarily serving the healthcare, pharmaceutical, and medical device industries. The company's mission is to help customers create a healthier and safer world by providing innovative healthcare and life science solutions. STERIS operates within the Healthcare sector, specifically in the Medical Equipment and Industrial Specialties industries. Its diverse product and service portfolio is categorized into Healthcare, Life Sciences, Applied Sterilization Technologies (AST), and Dental (Divested) segments.

STERIS Plc has a significant global presence, with operations spanning North America, Latin America, Europe, Asia, and the Middle East & Africa. The company primarily generates revenue from the United States (approximately 73% of net sales), followed by other international regions (25.4%) and Ireland (1.6%). STERIS utilizes a direct sales force in developed markets and a network of distributors in other selected markets to reach its diverse customer base worldwide.

STERIS Plc maintains a strong brand reputation due to its market position in infection prevention and consistent financial performance. Its products and services are critical in healthcare, pharmaceutical manufacturing, and medical device production, contributing to steady demand. The company's focus on environmentally friendly products also supports its reputation.

STERIS Plc features a mixed ownership structure, with a significant majority held by institutional investors. As of December 31, 2024, institutional investors owned approximately 93.22% of STERIS plc stock, individual retail investors held around 4.88% of shares, and insiders owned 0.93%. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., and Massachusetts Financial Services Co.